Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Oncoimmunology|May 6, 2015
Targeting tumor-associated macrophages in cancer therapy and understanding their complexityMichael A Cannarile, Carola H Ries, Sabine Hoves, et al.Current Opinion in Pharmacology|June 9, 2015
CSF-1/CSF-1R targeting agents in clinical development for cancer therapyCarola H Ries, Sabine Hoves, Michael A Cannarile, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 8, 2004
The role of dendritic cells in selection of classical and nonclassical CD8+ T cells in vivoMichael A Cannarile, Nadege Decanis, Joost P M van Meerwijk, et al.European Journal of Immunology|February 4, 2010
Parenchymal cells critically curtail cytotoxic T-cell responses by inducing Bim-mediated apoptosisAnton Gruber, Michael A Cannarile, Cedric Cheminay, et al.Journal for Immunotherapy of Cancer|July 19, 2017
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapyMichael A Cannarile, Martin Weisser, Wolfgang Jacob, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2021
Biomarker Technologies to Support Early Clinical Immuno-oncology Development: Advances and InterpretationMichael A Cannarile, Bruno Gomes, Marta Canamero, et al.Molecular Cancer Therapeutics|September 2, 2016
Macrophage Susceptibility to Emactuzumab (RG7155) TreatmentLeon P Pradel, Chia-Huey Ooi, Solange Romagnoli, et al.Proceedings of the National Academy of Sciences of the United States of America|November 4, 2009
Transcriptional regulator Id2 controls survival of hepatic NKT cellsLaurel A Monticelli, Yang Yang, Jamie Knell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2023
Facts and Hopes on Biomarkers for Successful Early Clinical Immunotherapy Trials: Innovative Patient Enrichment StrategiesMichael A Cannarile, Vaios Karanikas, Bernhard Reis, et al.Nature Immunology|November 7, 2006
Transcriptional regulator Id2 mediates CD8+ T cell immunityMichael A Cannarile, Nicholas A Lind, Richard Rivera, et al.Pageof 3